Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  dabrafenib
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6134, NCI-2014-01747, NCT02224781
Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients with Stage IIIC-IV Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1221, NCI-2013-01320, SWOG-S1221, NCT01902173
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20120238, NCI-2014-01974, NCT02110355
Dabrafenib, Trametinib, and Navitoclax in Treating Patients with BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9466, NCI-2013-02103, 13-424, NCT01970956, NCT01989585
Dabrafenib and Stereotactic Radiosurgery in Treating Patients With Melanoma and Brain Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC # 12857, NCI-2012-02214, NCT01721603
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116521, NCI-2014-01364, NCT01978236
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117019, NCI-2014-00802, NCT02034110
Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1320, NCI-2014-01470, NCT02199730, S1221, NCT02196181
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EAY131, NCI-2015-00054, NCT02465060
Dabrafenib and Trametinib in Treating Patients with Erdheim Chester Disease and BRAF Mutation
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 9598, NCI-2014-02197, 15-HG-0006, NCT02281734, T-HG-0112, NCT02281760
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 114144, NCI-2011-02757, NCT01231594
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 month to 17 years
Trial IDs: 116013, NCI-2013-00631, NCT01677741
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9354, NCI-2013-01748, 13-061, NCT01947023
Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients with Recurrent Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9557, NCI-2014-00615, 14-186, CTEP#9557, NCT02097225
Ipilimumab with or without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients with Melanoma That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9377, NCI-2013-01703, 13-304, NCT01938703, NCT01940809
Dabrafenib, Trametinib, and Digoxin in Treating Patients with BRAF V600 Mutant Melanoma That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STU 102015-074, NCI-2016-01832, NCT02915666
Dabrafenib and Radioactive Iodine in Treating Patients With Papillary Thyroid Carcinoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-337, NCI-2012-00817, NCT01534897
Dabrafenib in Treating Patients with BRAF Mutated Ameloblastoma
Status: Not yet active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ENT0043, NCI-2015-00169, NCT02367859
Start Over